A detailed history of Rockefeller Capital Management L.P. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Rockefeller Capital Management L.P. holds 92,867 shares of CRSP stock, worth $3.69 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
92,867
Previous 94,027 1.23%
Holding current value
$3.69 Million
Previous $5.08 Million 14.08%
% of portfolio
0.01%
Previous 0.01%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$44.62 - $62.75 $51,759 - $72,790
-1,160 Reduced 1.23%
92,867 $4.36 Million
Q2 2024

Aug 12, 2024

BUY
$51.17 - $68.18 $762,791 - $1.02 Million
14,907 Added 18.84%
94,027 $5.08 Million
Q1 2024

May 14, 2024

SELL
$60.67 - $89.12 $59,153 - $86,892
-975 Reduced 1.22%
79,120 $5.39 Million
Q4 2023

Feb 14, 2024

BUY
$38.62 - $72.18 $217,083 - $405,723
5,621 Added 7.55%
80,095 $5.01 Million
Q3 2023

Nov 14, 2023

BUY
$45.39 - $59.0 $41,577 - $54,044
916 Added 1.25%
74,474 $3.38 Million
Q2 2023

Aug 14, 2023

SELL
$43.47 - $67.77 $157,274 - $245,191
-3,618 Reduced 4.69%
73,558 $4.13 Million
Q1 2023

May 17, 2023

SELL
$41.0 - $56.12 $147,190 - $201,470
-3,590 Reduced 4.44%
77,176 $3.49 Million
Q4 2022

Mar 06, 2023

SELL
$39.19 - $65.67 $574,760 - $963,116
-14,666 Reduced 15.37%
80,766 $3.28 Million
Q3 2022

Nov 02, 2022

BUY
$61.1 - $83.78 $4.9 Million - $6.71 Million
80,146 Added 524.31%
95,432 $6.24 Million
Q2 2022

Aug 12, 2022

SELL
$43.23 - $73.83 $364,515 - $622,534
-8,432 Reduced 35.55%
15,286 $928,000
Q1 2022

May 13, 2022

BUY
$53.19 - $79.24 $2,978 - $4,437
56 Added 0.24%
23,718 $1.49 Million
Q4 2021

Feb 14, 2022

BUY
$70.09 - $111.29 $460,421 - $731,064
6,569 Added 38.43%
23,662 $1.79 Million
Q3 2021

Nov 12, 2021

BUY
$110.2 - $156.64 $1.49 Million - $2.12 Million
13,550 Added 382.44%
17,093 $1.91 Million
Q2 2021

Aug 10, 2021

SELL
$100.84 - $161.89 $106,184 - $170,470
-1,053 Reduced 22.91%
3,543 $573,000
Q1 2021

May 11, 2021

SELL
$110.72 - $210.04 $137,514 - $260,869
-1,242 Reduced 21.27%
4,596 $560,000
Q4 2020

Feb 12, 2021

BUY
$79.67 - $173.23 $105,244 - $228,836
1,321 Added 29.25%
5,838 $893,000
Q3 2020

Nov 13, 2020

BUY
$78.5 - $100.64 $62,957 - $80,713
802 Added 21.59%
4,517 $377,000
Q2 2020

Aug 12, 2020

BUY
$38.5 - $76.05 $77,000 - $152,100
2,000 Added 116.62%
3,715 $273,000
Q1 2020

May 12, 2020

SELL
$33.68 - $62.53 $4,445 - $8,253
-132 Reduced 7.15%
1,715 $72,000
Q4 2019

Feb 07, 2020

SELL
$36.68 - $73.13 $917 - $1,828
-25 Reduced 1.34%
1,847 $112,000
Q3 2019

Nov 12, 2019

SELL
$40.99 - $52.56 $4,385 - $5,623
-107 Reduced 5.41%
1,872 $77,000
Q2 2018

Jul 31, 2018

BUY
$42.62 - $73.59 $84,344 - $145,634
1,979 New
1,979 $116,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.1B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Rockefeller Capital Management L.P. Portfolio

Follow Rockefeller Capital Management L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

News

Stay updated on Rockefeller Capital Management L.P. with notifications on news.